Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · men and women aged over 18 years with chronic fatigue syndrome
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension with seizures · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Muscle strength · boys with DMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Muscle strength: maximum voluntary isometric knee extension strength · people with facioscapulohumeral muscular dystrophy
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · young women with suspected primary dysmenorrhoea
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · young women with suspected primary dysmenorrhoea
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with painful diabetic neuropathy
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with postherpetic neuralgia
1 finding from 1 review
Type of adverse event: allergic reactions/hypotension · people with CKD
Patient‐centred outcomes for oral may leads to higher type of adverse event: allergic reactions/hypotension compared with IV iron (low certainty).
1 finding from 1 review